The greatest prevalence of back symptoms and sciatica in the Finnish female population occurs just after menopause, at between 55 and 64 years, and it starts to increase between 45 and 54 years of age [21] . In an epidemiological study, increased risk of back symptoms without known etiology exists within those who have had premature menopause [1] . Spinal mobility is one aspect of back performance that has been shown by cross-sectional studies to decrease with age and spinal degeneration [5, 7, 29, 31, 37, 42, 45, 47] . The fibrocartilaginous intervertebral discs between the vertebrae allow the spine to bend and twist with hydraulic properties. The discs, ligaments, and zygoapophyseal joints, and especially the collagen in them, restrict spinal mobility [13, 23, 47] . Human intervertebral discs consist of eight different types of collagen [23, 47] . Collagen type I is predominant in the outer annulus fibrosus and collagen type II in the inner layers [11, 47] . Collagen type I is thought to provide the tensile properties of the annulus fibrosus and other tissues [23] . The tensile properties of collagen depend largely upon the formation of intermolecular cross-links between the constituent molecules [13] . The changes in the proportions of the different collagen types in the spine along with aging and the Abstract The purpose of this study was to examine the influence of estrogen-progestin replacement therapy and exercise on the lumbar spine mobility and back symptoms of early postmenopausal women. The population sample consisted of 78 healthy, 49-to 55-year-old women, 0.5-5 years after menopause, who were randomized into three groups, two receiving different protocols of estradiol valerate combined with medroxyprogesterone acetate replacement therapy, and the third group a placebo. These groups were then randomized into exercise and control cases and monitored for 2 years. The mobility of the lumbar spine was measured and symptoms investigated using the Million and Oswestry pain and disability questionnaires and pain drawings at the baseline and after 1 and 2 years. During the followup, the mobility of the lumbar spine decreased in all six groups. The decrease was most evident in those who had been the most flexible at baseline (P < 0.0001). The decrease was less notable in the hormone replacement therapy groups than in the control group. When the replacement therapy groups were pooled together, the difference was significant at a P < 0.05 level. No difference was seen between the hormone combinations. The exercise intervention was insufficient to influence lumbar spine mobility. Only sporadic cases of back symptoms appeared and disappeared among the subjects during the follow-up, and no preventive or aggravating effects of hormone replacement therapy or the exercise program on symptoms were detected.
Introduction
The greatest prevalence of back symptoms and sciatica in the Finnish female population occurs just after menopause, at between 55 and 64 years, and it starts to increase between 45 and 54 years of age [21] . In an epidemiological study, increased risk of back symptoms without known etiology exists within those who have had premature menopause [1] . Spinal mobility is one aspect of back performance that has been shown by cross-sectional studies to decrease with age and spinal degeneration [5, 7, 29, 31, 37, 42, 45, 47] . The fibrocartilaginous intervertebral discs between the vertebrae allow the spine to bend and twist with hydraulic properties. The discs, ligaments, and zygoapophyseal joints, and especially the collagen in them, restrict spinal mobility [13, 23, 47] . Human intervertebral discs consist of eight different types of collagen [23, 47] . Collagen type I is predominant in the outer annulus fibrosus and collagen type II in the inner layers [11, 47] . Collagen type I is thought to provide the tensile properties of the annulus fibrosus and other tissues [23] . The tensile properties of collagen depend largely upon the formation of intermolecular cross-links between the constituent molecules [13] . The changes in the proportions of the different collagen types in the spine along with aging and the Abstract The purpose of this study was to examine the influence of estrogen-progestin replacement therapy and exercise on the lumbar spine mobility and back symptoms of early postmenopausal women. The population sample consisted of 78 healthy, 49-to 55-year-old women, 0.5-5 years after menopause, who were randomized into three groups, two receiving different protocols of estradiol valerate combined with medroxyprogesterone acetate replacement therapy, and the third group a placebo. These groups were then randomized into exercise and control cases and monitored for 2 years. The mobility of the lumbar spine was measured and symptoms investigated using the Million and Oswestry pain and disability questionnaires and pain drawings at the baseline and after 1 and 2 years. During the followup, the mobility of the lumbar spine decreased in all six groups. The decrease was most evident in those who had been the most flexible at baseline (P < 0.0001). The decrease was less notable in the hormone replacement therapy groups than in the control group. When the replacement therapy groups were pooled together, the difference was significant at a P < 0.05 level. No difference was seen between the hormone combinations. The exercise intervention was insufficient to influence lumbar spine mobility. Only sporadic cases of back symptoms appeared and disappeared among the subjects during the follow-up, and no preventive or aggravating effects of hormone replacement therapy or the exercise program on symptoms were detected.
Influence of estrogen-progestin replacement therapy and exercise on lumbar spine mobility and low back symptoms in a healthy early postmenopausal female population: a 2-year randomized controlled trial changes in the collagen and elastin molecules cross-linking are thought to induce increasing stiffness with dehydration of the intervertebral discs [12, 13, 36, 47] . Endogenous estrogen production decreases in menopause and causes menopausal symptoms [25] . The estrogen influences collagen type I metabolism [17-20, 22, 41] , and clinical hormone replacement trials have been carried out mainly with estrogens and on the formation and degradation markers of type I collagen [17] [18] [19] [20] 41] . A variety of back exercise programs have been suggested to prevent and reduce back symptoms [40] . The correlation between mobility and back symptoms has previously been disputed [5-7, 28, 29] . The purpose of this study was to examine the influence of estrogen-progestin replacement therapy and exercise on lumbar spine mobility, their possible aggravating or preventive effects on the back symptoms of healthy, early postmenopausal women, and their possible synergy.
Material and methods
This study was conducted on a population sample of 78 healthy 0.5-to 5-years postmenopausal women aged 49-55 years [24] . The main characteristics of the subjects are shown in Table 1 . The 78 subjects were divided randomly into three groups of 26 subjects each. The first received cyclically 2 mg estradiol valerate (E 2 V) for 11 days and 2 mg E 2 V with 10 mg medroxyprogesterone acetate (MPA) for 10 days and placebo tablets for 7 days. The second group received 2 mg E 2 V for 70 days, 2 mg E 2 V and 20 mg MPA for 14 days and a placebo for 7 days, i.e., progestin every 3rd month. The third group took a placebo only. Each of these three groups was then subdivided so that one half pursued a training program of one guided 1-h exercise at a fitness center per week, while the other half did not, and all groups were followed up for 2 years. The hour of exercise was made up of 10 min warm-up, 40 min exercising on various machines, including weight lifting, bending, and sometimes playing games, swimming and jogging for a change, with a 10-min period of stretching at the beginning and the end of each session.
Additionally, the same subjects had a 1-h exercise session twice a week by themselves. The other halves of the groups served as exercise controls in this respect. All subjects kept a diary of their daily activities. Reports of the quantity of guided exercise hours were obtained from the physiotherapists and from the subjects themselves, showing the number of private 1-h exercises.
Measurements
The lumbar spine mobility tests were performed at 0, 12, and 24 months, between 2 p.m. and 7 p.m. Each subject warmed up for 5 min on a bicycle ergometer without a load before the actual testing. The measurement of lumbar extension and flexion mobility was performed with a flexicurve [8] and that of maximal lateral flexion with a middle finger sliding on the femoral side [27] , at 0, 12, and 24 months. The total mobility index was created by summing up the extension, flexion, and lateral flexions. The previous back pain periods and actual back symptoms were investigated using Million visual analog scales [30, 40] , pain drawings [47] , and Oswestry disability scores [14] . The tester and the subjects were unaware of the results of the previous measurements, and the tester did not know whether the subjects belonged to the hormone or training group or not. Elevated serum follicle-stimulating hormone (FSH) concentrations were ascertained to confirm the postmenopausal status of the study subjects. Regular blood samples were taken, including serum estradiol levels, to control whether the subjects took the pills. The cardiovascular capacity of each subject was tested before and during the trial at 0, 12 and 24 months by means of a bicycle ergometer test -anaerobic threshold and a continuous electrocardiogram was recorded under the supervision of a physician [24] .
The statistical analyses were performed using the repeated measures ANOVA (Solo). The research was carried out in strict conformity with the Helsinki Declaration and the guidelines of the American College of Sports Medicine, and the trial protocol was evaluated and accepted by Ethical Committee at the Deaconess Institute Hospital in Oulu, Finland.
Results
The intratester reproducibility of the tests has been reported previously [24] . Serum FSH concentrations (49-67 IU/l) confirmed the postmenopausal status of the study subjects at the beginning. The serum estradiol levels increased as expected in both hormone groups. At the baseline eight subjects reported having back symptoms during the previous week, two of them transient pain. Sixtyseven of the 78 subjects reported at least one previous episode of back pain during their lifetime. No statistical differences were seen between the groups. There were 13 drop-outs (16.7%) among the 78 participants during the 1st year, and four drop-outs during the 2nd year. Altogether 61 subjects (21.8%) attended the final stage of the study; the distribution of drop-outs across the groups is shown in Table 2 . The dropping out was due to back problems in four cases -sciatica in one case, severe back pain in the remaining three -and reluctance to participate in the measurements in three cases. The three drop-out cases with severe back pain were in groups 1, 4 and 5, and that with sciatica was in group 4. Other reasons for discontinuation were: no follow-up data in two cases, various psychological symptoms in one case, thrombosis in the leg after a hip operation in one case, fatal myocarditis in one case, ischemic papillopathy in the left eye in one case, breast cancer in one case, and long withdrawal bleedings in two cases. In the exercise groups, 28 subjects reported increased exercise at one year in comparison to the previous years amount while five reported no change. In the control groups, the subjects reported unchanged exercise in 27 cases, an increase in three cases and a decrease in two cases. Attendance at the guided exercise events varied from 80 to 92%, being similar in the different exercise groups. The mean number of the additional self-exercise events was also similar in the exercise groups, with the exception of group 4 -E 2 V and MPA II and exercise -which also had 5 drop-outs (Table 2) . During the followup, the mean lumbar spine mobility index (extension + flexion + lateral flexions; initial mean 312, range 245-557) decreased in all groups. The decrease was most evident among those who were most flexible initially (P < 0.0001) (Fig. 1) . The mean decrease was smaller in the hormone replacement therapy groups (from 410 to 390 points) than in the control group (from 410 to 365 points). When the hormone replacement therapy groups were pooled together and compared with the control group, the difference was found to be statistically significant (P < 0.05) (Fig. 2) . No statistical difference existed between the hormone combinations. Among the other subjects a small number of mild occasional symptoms appeared and disappeared during the follow-up. There were no systematic trends or statistical differences in the symptoms between the hormone and exercise groups. No preventive or aggravating effects of the hormone replacement therapy or the exercise program on back symptoms were found. The exercise program did not influence lumbar spine mobility in this study. No significant correlations were seen between the changes in the mobility index and symptoms. The Million questionnaires revealed no differences in felt back stiffness between the groups. The pain drawings also failed to reveal differences in symptoms between the groups.
Discussion
Previous cross-sectional mobility studies have suggested that spinal mobility is poorer in older age groups than in 383 1 Inverse relationship between the lumbar spine mobility index at baseline and the change during the 2-year follow-up. The mobility decrease was most evident in those who were the most flexible at the baseline (P < 0.001) Fig. 2 Influence of estrogen-progestin replacement therapy on lumbar spine mobility index (mean ± 1 SD). The mobility decreases in all groups but less so in the hormone groups, 1 and 2. When the hormone group results were pooled, the difference was statistically significant (P < 0.05) younger groups, but that notable individual differences exist [5, 7, 29, 31, 37, 42] . This study shows a new finding, that the mobility of the lumbar spine decreases in the early postmenopausal period. The mean decrease in the mobility index in this study was 20 points in the hormone replacement therapy groups and 45 points in the control group -about 5% and 11% of the total index, and even more of the range. It is difficult to compare the rate of decrease in relation to the decrease at other ages, because of the lack of follow-up studies and reference data. All the previous age-related mobility studies have been cross-sectional [5, 7, 29, 31, 37, 42] . We think that an 11% decrease over 2 years is quite large in this healthy study group. Spinal mobility is an important part of back performance, and the decrease in mobility is of clinical importance if it increases clumsiness and the stiffness changes the biomechanical properties of the discs and spine. The difference between the hormone replacement therapy groups and the control group can also reveal interesting things about the influences of hormones on connective tissue metabolism [20] and possibly on fluid retention of intervertebral discs, and is important in terms of the prevention of subsequent increase of back stiffness. This connection has been suggested previously by epidemiological evidence on the possible preventive influences of estrogen replacement therapy on knee and hip osteoarthritis obtained by the Osteoporotic Fractures Research Group and the Framingham Osteoarthritis Study [15, 33] . There are also some experimental animal studies available that show a possible connection between hormone levels and receptors in cartilage [34, 44] .
In recent years, much attention has been directed towards the rapid postmenopausal decrease in bone mineral density along with the decreasing endogenous estrogen production and the prevention of osteoporosis with estrogens [17] [18] [19] [20] 41] . Medroxyprogesterone acetate has been suggested to have some dose-dependent anabolic and androgenic or antiandrogenic activity on muscles [35] , and it has been shown that MPA therapy alone prevents bone loss in postmenopausal women [26] . The simultaneous changes in other connective tissues apart from bones and muscles have been unclear, although there is a correlation between bone mineral density and muscle strength, and it has also been suggested that a causal relationship exists between them [24] . We have reported separately simultaneous positive effect of E 2 V and MPA on bone mineral density, collagen type I metabolism and muscle strength seen in this study [20] . The clinical collagen studies are mostly made on the formation and degradation markers of type I collagen, which is located predominantly in bone, but also in the annulus fibrosus of intervertebral discs, skin, tendons, and muscles. The blood sample measurements of collagen metabolism are collagen specific rather than tissue specific. Aging changes the distribution of different collagens [9, 12, 36] , and alterations also occur in the structure of collagens in discs and ligaments [13, 32, 47] .
The precise mechanism of estrogen influence on collagen I metabolism is not known. There are few clinical studies of the influence of estrogens on other collagens because of a lack of simple biochemical markers. Our study failed to show any correlations between the changes in symptoms and the changes in mobility index. The previous results on this connection have also been inconclusive [5-7, 28, 29, 40] . Unspecific effect of hormones due to increased activity and vitality can not be excluded. The exercise program in this study was insufficient to significantly prevent the decrease of lumbar spine mobility, contrary to results of the canine study, in which long-term running exercises seemed to activate collagen metabolism in the posterior annulus fibrosus of the intervertebral discs [38] . Some animal studies suggest that immobilization induces changes in periarticular connective tissue metabolism and increases the rate of collagen turnover, making the formation-degradation balance negative [2, 4] , while stress decreases the turnover speed and makes the balance positive [3, 43] . The exercise program possibly did not concentrate sufficiently on mobility exercises. The present subjects were not back pain patients, but healthy women, and new low back symptoms were hence rare. The E 2 V and MPA replacement therapy and exercise did not have any effect on back symptoms in the study group. Many confounders may also exist. The groups and subgroups may have been too small to yield statistical differences; this would also lessen the significance of negative conclusions. The follow-up time of 24 months, may also have been too short, or there may have been neither preventive nor aggravating effects.
Conclusions
Our conclusions are that spinal mobility decreases in early postmenopause, especially in the subjects who are most flexible initially, and that estrogen-progestin replacement therapy slightly reduces this decrease. No hormonal or exercise effects on back symptoms in this healthy female population sample were found.
